Dibasic Sodium Phosphate Veterinary Grade API is supplied under product designations DSP-Vet/ANH for the anhydrous form (CAS 7558-79-4), DSP-Vet/DH for the dihydrate (CAS 10028-24-7), and DSP-Vet/DDH for the dodecahydrate (CAS 10039-32-4). The material is intended for manufacture of veterinary dosage forms including tablets, injections, capsules, powders, granules, premix, and solutions. The primary technical functions are pH buffering, osmotic adjustment, and controlled sodium/phosphate electrolyte delivery. The substance complies with the current USP-NF monograph for Dibasic Sodium Phosphate and the Ph.Eur. and BP monographs for disodium phosphate where the relevant hydrate form is specified. Veterinary designation does not imply reduced chemical purity; it defines the regulatory documentation, GMP release pathway, and intended animal species use under Regulation (EU) 2019/6 and applicable 21 CFR 210/211 requirements for finished dosage forms. API manufacture follows ICH Q7 and EU GMP Part II.

The product is differentiated from reagent-grade or food-grade sodium phosphate by the absence of non-pharmaceutical additives, control of bacterial endotoxins where required for parenteral grades, compendial identity verification, and defined hydrate-specific loss on drying. In direct-compression tablet formulations, the typical inclusion range is 1–10% w/w as a buffering filler, while parenteral solutions commonly use 0.5–2.0% w/v depending on the target pH and tonicity contribution. For low-dose premix and oral powders, particle-size control is used to reduce segregation: a representative direct-compression specification is D₅₀ 100–180 µm with D₉₀ ≤ 250 µm. Milled or granulated grades are selected according to flowability and bulk density requirements. Each hydrate has a different water activity and sodium content per unit mass, which affects formulation calculations and stability studies.

What limits dibasic sodium phosphate in parenteral manufacturing?

The use of dibasic sodium phosphate in injectable formulations is constrained primarily by pH, cation compatibility, and endotoxin control. A 1 in 100 aqueous solution of the anhydrous or hydrated forms is alkaline, typically within the compendial release range of pH 8.5–9.6 when measured by USP <791>. This pH is suitable for adjusting acidic active pharmaceutical ingredients toward physiological pH, but it can exceed the stability window of hydrolysis-sensitive molecules. Phosphate also precipitates with calcium and magnesium ions; therefore, injectable formulations containing calcium gluconate, calcium chloride, or magnesium sulfate require explicit compatibility testing because insoluble calcium phosphate or magnesium phosphate can form above the ion product threshold. For parenteral use, bacterial endotoxin limits are product-specific and derived from the maximum adult or target animal dose according to USP <85>; the limit is calculated from the formula K/M, where K is the threshold pyrogenic dose per kilogram and M is the maximum administered dose per kilogram per hour. Thus, the API endotoxin specification cannot be fixed universally but must be agreed between the API manufacturer and the finished-product marketing authorization holder. The material should also be evaluated for particulate matter after terminal sterilization because heat sterilisation can alter hydrate-water content and potentially affect reconstitution time.

Injection-grade dibasic sodium phosphate should be processed from low-endotoxin water and packaged in sealed, moisture-barrier containers. An operational boundary commonly applied during pharmaceutical handling is storage below 60% RH for the anhydrous grade after opening, because uptake of atmospheric moisture changes the effective hydrate state and can shift the nominal phosphate content per unit mass. Uncontrolled moisture uptake is not a purity failure, but it alters lot-to-lot mass-based charging accuracy in electrolyte-containing parenteral or oral formulations. The use of nitrogen-blanketed containers is not routinely required, but drying and storage records should be maintained to support batch consistency.

Anhydrous, dihydrate, and dodecahydrate crystal forms

Hydrate state is not an interchangeable parameter. The three supplied models differ in molecular mass, water content, sodium content, and energy of dissolution. The anhydrous form has a formula weight of 141.96 g/mol, the dihydrate 177.99 g/mol, and the dodecahydrate 358.14 g/mol. Compendial loss on drying reflects the bound water: for the anhydrous material the loss is generally not more than 5.0%, for the dihydrate the range is approximately 18.0–21.0%, and for the dodecahydrate the range is approximately 55.0–64.0%. The exact ranges are fixed by the current compendial monograph and should be quoted from the relevant edition. These differences directly affect the amount required to deliver a given anhydrous equivalent phosphate concentration. Use of the dodecahydrate in a formulation calculated on an anhydrous basis without correction can cause a phosphate underdose or sodium imbalance.

For solid oral dosage forms, the hydrate state influences compaction behaviour. The anhydrous form is hygroscopic and may compact poorly if surface moisture is not controlled; the dodecahydrate contains more water and can reduce friction but may require adjustment of granulation water. Therefore, selection should be based on the unit operation rather than chemical purity alone.

In oral electrolyte powders and veterinary premixes, dibasic sodium phosphate is often combined with sodium chloride, potassium chloride, sodium citrate, and glucose or dextrose carriers. The hydration state should be accounted for in sodium and phosphate label claims. The dodecahydrate may contribute less sodium per gram than the anhydrous material because of its higher water of crystallisation. This can affect the final osmolality and sodium-to-phosphate ratio in oral rehydration formulations. Standard practice uses an assayed phosphate value on the certificate of analysis to calculate the equivalent anhydrous dibasic concentration. Premix homogeneity is controlled by sieve analysis and blend uniformity testing according to ASTM D6913 or equivalent pharmacopoeial particle-size methods.

When direct compression displaces wet granulation in tablet production

Direct compression with dibasic sodium phosphate is chosen when the drug substance is moisture-sensitive and wet granulation is undesirable. The phosphate is used as a buffering excipient or filler, but its flowability and compressibility are inferior to microcrystalline cellulose and lactose monohydrate. Tablet presses require gravity feed or force-feeder control to manage bulk density variability. The anhydrous grade is milled to a free-flowing particle distribution, but the material can adhere to tooling at low relative humidity due to electrostatic charging. Sodium stearyl fumarate at 0.5–1.0% w/w or magnesium stearate at 0.5% w/w is used as lubricant; excessive lubricant can lower tablet tensile strength and prolong disintegration. The phosphate functions as a soluble filler and buffering agent, but it does not provide plastic deformation comparable to microcrystalline cellulose. Therefore, higher compression force may be necessary to achieve acceptable hardness. Tablet ejection force and upper punch sticking should be monitored on rotary presses. Pre-drying at 105 °C for the anhydrous grade is used when storage RH exceeds 60%, because surface moisture can cause punch filming. The published direct-compression data for this specific veterinary grade is limited; formulation optimisation must be performed on the actual product model and not transferred from other phosphate salts.

In capsule filling, dibasic sodium phosphate may be used as a buffering diluent, but its high water solubility can accelerate capsule-shell brittleness if the formulation is stored at low humidity. The phosphate should be combined with fillers that moderate moisture transfer. Capsule fill weight and tamping pin setting on dosator or tamping-pin machines must account for the bulk density difference between the anhydrous and dodecahydrate grades. A bulk density range of 0.7–0.9 g/cm³ is typical for milled anhydrous material, but lot-specific values should be used for volume-based filling.

Buffering capacity in oral electrolyte premix depends on pKₐ₂ and ionic strength

Dibasic sodium phosphate buffers most effectively near the second dissociation constant of phosphoric acid. At 25 °C the thermodynamic pKₐ₂ is approximately 7.20. The practical pH range for phosphate buffering is therefore approximately 6.2–8.2, although the exact midpoint shifts with ionic strength and temperature. In concentrated oral solutions or premix reconstitution fluids, the apparent pKₐ₂ is lower than the thermodynamic value because ionic interactions stabilise the charged phosphate species. Formulation calculations should use the apparent pKₐ₂ corrected by the Debye-Hückel or specific-ion-interaction approach, not the dilute-solution value. This is important when the same phosphate is used to buffer an oral antibiotic solution at pH 7.4: the ratio of hydrogen phosphate to dihydrogen phosphate is not simply 1:1 under physiological ionic strength.

Differences from other sodium phosphate salts are material. Monobasic sodium phosphate lowers pH and buffers near pKₐ₁, approximately 2.1, and therefore cannot be used as a neutral-pH buffer alone. Trisodium phosphate is strongly alkaline and is used mainly for cleaning or high-pH pharmaceutical processes, not for neutral dosage forms. Dipotassium phosphate provides similar buffering near pKₐ₂ but delivers potassium instead of sodium. This substitution is relevant in veterinary formulations where sodium restriction is required for renal or cardiovascular disease. The table below summarises these differences for formulation selection.

For solution-based veterinary products, the dissolved phosphate species is kinetically available for acid-base buffering, while calcium phosphate is essentially insoluble and is unsuitable for clear solutions. The selection between dibasic sodium phosphate and dipotassium phosphate is based on total cation contribution: a 1 mmol/L solution of Na₂HPO₄ delivers 2 mmol/L of sodium, whereas the same phosphate buffer from K₂HPO₄ delivers 2 mmol/L of potassium. In polyionic oral rehydration solutions this difference changes the calculated osmolar gap and should be verified by freezing-point depression osmometry according to USP <785> or equivalent pharmacopoeial method.

In granulated premix and powder production, dibasic sodium phosphate can raise the pH of the local moisture phase during high-shear wet granulation. This favours stability of acid-labile actives but may accelerate base-catalysed degradation of ester-containing drugs. The granulation process should therefore be evaluated by stress stability trials at elevated temperature and controlled RH. Because the phosphate holds water of crystallisation, granulation water addition must be reduced when using the dodecahydrate. Failure to correct for this water contribution can produce overwetted granulations, oversized agglomerates, and variable drying times in fluid-bed dryers.